233 related articles for article (PubMed ID: 31179560)
1. A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3.
Sakane T; Murase T; Okuda K; Saida K; Masaki A; Yamada T; Saito Y; Nakanishi R; Inagaki H
Histopathology; 2019 Nov; 75(5):755-766. PubMed ID: 31179560
[TBL] [Abstract][Full Text] [Related]
2. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
[TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients.
Tong L; Yang XX; Liu MF; Yao GY; Dong JY; Ye CS; Li M
Asian Pac J Cancer Prev; 2012; 13(11):5599-603. PubMed ID: 23317280
[TBL] [Abstract][Full Text] [Related]
4. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
5. Mutation analysis of the EGFR gene and its downstream signaling pathway in thymic carcinoma patients from a Chinese Han population.
Zhan P; Chen X; Wu XY; Hou ZB; Qian Q; Zhang Y; Zou J; Zhang YQ; Wan MY; Wang JD; Yu LK; Xie HY
Clin Respir J; 2018 Feb; 12(2):601-607. PubMed ID: 27731926
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological significance of EGFR pathway gene mutations and CRTC1/3-MAML2 fusions in salivary gland mucoepidermoid carcinoma.
Morita M; Murase T; Okumura Y; Ueda K; Sakamoto Y; Masaki A; Kawakita D; Tada Y; Nibu KI; Shibuya Y; Inagaki H
Histopathology; 2020 Jun; 76(7):1013-1022. PubMed ID: 32129900
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Cohen Y; Goldenberg-Cohen N; Shalmon B; Shani T; Oren S; Amariglio N; Dratviman-Storobinsky O; Shnaiderman-Shapiro A; Yahalom R; Kaplan I; Hirshberg A
Oral Oncol; 2011 Oct; 47(10):946-50. PubMed ID: 21824802
[TBL] [Abstract][Full Text] [Related]
9. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
[TBL] [Abstract][Full Text] [Related]
10. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
11. Combined mutational analysis of RAS, BRAF, PIK3CA, and TP53 genes in Taiwanese patients with oral squamous cell carcinoma.
Chang YS; Hsu HT; Ko YC; Yeh KT; Chang SJ; Lin CY; Chang JG
Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Jul; 118(1):110-116.e1. PubMed ID: 24908601
[TBL] [Abstract][Full Text] [Related]
12. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
Sclafani F; Wilson SH; Cunningham D; Gonzalez De Castro D; Kalaitzaki E; Begum R; Wotherspoon A; Capdevila J; Glimelius B; Roselló S; Thomas J; Tait D; Brown G; Oates J; Chau I
Int J Cancer; 2020 Jan; 146(1):94-102. PubMed ID: 31199501
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Wang L; Hu H; Pan Y; Wang R; Li Y; Shen L; Yu Y; Li H; Cai D; Sun Y; Chen H
PLoS One; 2014; 9(2):e88291. PubMed ID: 24533074
[TBL] [Abstract][Full Text] [Related]
14. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
[TBL] [Abstract][Full Text] [Related]
15. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
[TBL] [Abstract][Full Text] [Related]
16. Mutation analysis of the EGFR pathway genes,
Saida K; Murase T; Ito M; Fujii K; Takino H; Masaki A; Kawakita D; Ijichi K; Tada Y; Kusafuka K; Iida Y; Onitsuka T; Yatabe Y; Hanai N; Hasegawa Y; Shinomiya H; Nibu KI; Shimozato K; Inagaki H
Oncotarget; 2018 Mar; 9(24):17043-17055. PubMed ID: 29682203
[TBL] [Abstract][Full Text] [Related]
17. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
[TBL] [Abstract][Full Text] [Related]
18. TP53 and EGFR Mutational Status in Thymoma: A Genetic Sequencing Study.
Syahruddin E; Zaini J; Sembiring R; Baginta R; Fadhillah MR; Noor DR
Asian Pac J Cancer Prev; 2022 Jan; 23(1):109-114. PubMed ID: 35092378
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels.
Mikhitarian K; Pollen M; Zhao Z; Shyr Y; Merchant NB; Parikh A; Revetta F; Washington MK; Vnencak-Jones C; Shi C
Mod Pathol; 2014 May; 27(5):665-74. PubMed ID: 24186143
[TBL] [Abstract][Full Text] [Related]
20. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
